Abstract:IMPORTANCE Loss of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression has been reported in several malignant tumors and predicts dismal survival outcomes. In gastric cancer, existing studies on this topic are limited and the association between MGMT and fluorouracil-based adjuvant chemotherapy remains obscure. OBJECTIVE To investigate the postoperative prognostic significance of MGMT in patients with resectable gastric cancer and its responsiveness to fluorouracil-based adjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS This study recruited 445 consecutive patients with resectable gastric cancer who underwent radical gastrectomy between August 1, 2007, and December 30, 2008, at Zhongshan Hospital at Fudan University in Shanghai, China. Patients were randomly divided into a discovery data set (n = 200) and a validation data set (n = 245), and the range of follow-up time was from 2 to 76 months for the discovery group and 2 to 79 months for the validation group. The immunoreactivity for MGMT in cancer cells was reviewed under a light microscope by 2 pathologists who were blinded to the clinicopathological data. The association of MGMT expression with clinicopathological characteristics and measures and prognosis was inspected. Data and specimens were collected from patients from the date of surgery to April 25, 2014. Data analysis took place from May 9, 2016, to July 15, 2016. MAIN OUTCOMES AND MEASURES Estimates of overall survival on the basis of MGMT expression and hazard ratio (HR) for estimates of overall mortality risk. RESULTS Of the 445 patients included in the study, 315 (70.8%) were men, and the mean (SD) age of all patients was 60 (12) years. Positive expression of MGMT indicated better overall survival for patients with stage II or III gastric cancer in both the discovery data set (HR, 0.52; 95% CI, 0.32-0.84; P =.003) and the validation data set (HR, 0.63; 95% CI, 0.43-0.93; P =.01). Multivariate analysis identified MGMT expression and TNM stage as 2 independent prognostic factors for overall survival. In stage II disease, the benefit from fluorouracil-based adjuvant chemotherapy was superior among MGMT-positive patients (HR, 0.35; 95% CI, 0.13-0.95; P =.007 for interaction) compared with MGMT-negative patients. CONCLUSIONS AND RELEVANCE Positive expression of MGMT in gastric cancer was identified as an independent, favorable prognostic factor. Incorporating MGMT expression into the current TNM staging system could lead to better prognostic accuracy. These findings should be confirmed within the framework of randomized clinical trials associated with genomic DNA sequencing studies.

The relationships between the expression of MGMT and prognosis in the advanced patients with gastric carcinoma

Relationship Between the P53 Functional Status of Human Tumor Cell Lines and Their Chemosensitivities to Different Anticancer Drug

Study on relationship between mutant p53 and multidrug resistance gene 1 in gastric cancer

O6-methylguanine DNA Methyltransferase is Upregulated in Malignant Transformation of Gastric Epithelial Cells Via Its Gene Promoter DNA Hypomethylation

Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.

Expression of ToPo Ⅱ,MRP,GST-π in Gastric Carcinoma and Its Relationship with Prognosis

[The Expression of O6-methylguanine DNA Methyltransferase and P53 in Non-Small Cell Lung Cancer and the Association with the Prognosis].

Relation Between Mutant P53 and Multidrug Resistance in Gastric Cancer

The Correlation of the Expression of MGMT and P53 in Human Brain Gliomas with Tumor Grade or Prognosis

Tumor and Serum Gamma-Glutamyl Transpeptidase, New Prognostic and Molecular Interpretation of an Old Biomarker in Gastric Cancer

O-6-Methylguanine-Dna Methyltransferase (Mgmt): Challenges And New Opportunities In Glioma Chemotherapy

Amino acid substitution polymorphisms of the DNA repair gene MGMT and the susceptibility to cervical carcinoma.

The Correlation between Aberrant Promoter Methylation of MGMT and Immunohistochemical Expression with Clinical Prognosis in Glioblastoma Multiforme

Downregulation of MGMT Promotes Proliferation of Intrahepatic Cholangiocarcinoma by Regulating P21

A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma

O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis

MGMT gene promoter methylation in malignant melanoma patients

Survival status of patients with esophageal squamous cell carcinoma in Yangzhong City and the prognostic significance of protein expressions of XRCC1 and MGMT

O-6-methylguanine-DNA Methyltransferase Inhibits Gastric Carcinoma Cell Migration and Invasion by Downregulation of Matrix Metalloproteinase 2.

Methylation of O6-methylguanine DNA Methyltransferase Promoter is a Predictive Biomarker in Chinese Melanoma Patients Treated with Alkylating Agents

The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis